Amneal Pharmaceuticals Q1 2024 Adj EPS $0.14 Beats $0.09 Estimate, Sales $659.191M Beat $619.033M Estimate
Amneal Pharmaceuticals Q1 2024 Adj EPS $0.14 Beats $0.09 Estimate, Sales $659.191M Beat $619.033M Estimate
Amneal Pharmaceals 2024年第一季度調整後每股收益0.14美元超過預期的0.09美元，銷售額6.59191億美元超過預期的6.19033億美元
Amneal Pharmaceuticals (NYSE:AMRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.09 by 55.56 percent. This is a 16.67 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $659.191 million which beat the analyst consensus estimate of $619.033 million by 6.49 percent. This is a 18.23 percent increase over sales of $557.540 million the same period last year.
Amneal Pharmicals（紐約證券交易所代碼：AMRX）公佈的季度收益爲每股0.14美元，比分析師普遍預期的0.09美元高出55.56％。這比去年同期每股收益0.12美元增長了16.67％。該公司公佈的季度銷售額爲6.59191億美元，比分析師普遍預期的6.19033億美元高出6.49％。這比去年同期的5.5754億美元的銷售額增長了18.23％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。